This Is What Whales Are Betting On Novo Nordisk
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
BofA Securities Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
Novo Nordisk Shares Unlikely to Move Ahead of New Drug Data -- Market Talk
Novo Nordisk's New Weight-Loss Jab Could Support Co Into 2030s -- Market Talk
Top Gap Ups and Downs on Tuesday: SAN, BBVA, ING and More
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could Be Next
Express News | Novo Nordisk Says Co Has Mitigation Plans In Place To Minimize Or Prevent Any Production Disruption Due To The Potential Seaport Strikes
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
Novo Nordisk (NVO) Poised for 23.3% Upside as Obesity Market Expands and Clinical Trials Impress
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
European Equities Traded in the US as American Depositary Receipts Open Week Lower
European medical care sector ends October's continuous rise, causing concern for pharmaceutical companies such as novo-nordisk a/s (NVO.US).
European healthcare stocks are on the verge of ending their longest rising trend since March 2010, due to market concerns over novo-nordisk a/s's upcoming third-quarter performance, as well as astrazeneca and roche's experimental drug updates.
Pharmaceutical industry becomes a key driver, Denmark's GDP growth in the second quarter exceeded expectations by 1.1%.
Denmark's economic growth rate is faster than previously expected.
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent Set to Advance in Top Drug Sales
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
Benzinga Bulls And Bears: Apple, Tesla, Novo Nordisk, Bitcoin — And Shiba Inu's Major Stablecoin Tease